- Home
- PHAR
PHAR
Pharming Group N.V.
as 12-18-2024 9:56am EST
Pharming Group is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. It is commercializing and developing an innovative portfolio of protein replacement therapies and precision medicines to serve the unserved rare disease patients. Its product includes Ruconest. The revenue is generated from the United States.
| Founded: | 1988 | Country: | Netherlands |
| Employees: | N/A | City: | N/A |
| Market Cap: | 627.5M | IPO Year: | N/A |
| Target Price: | $27.00 | AVG Volume (30 days): | 7.3K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.03 | EPS Growth: | N/A |
| 52 Week Low/High: | $6.65 - $13.20 | Next Earning Date: | 10-24-2024 |
| Revenue: | $285,745,000 | Revenue Growth: | 30.64% |
| Revenue Growth (this year): | 20.89% | Revenue Growth (next year): | 11.15% |
Latest Pharming Group N.V. News
PHAR Breaking Stock News: Dive into PHAR Ticker-Specific Updates for Smart Investing
MT Newswires
2 days ago
Pharming Group Commences Cash Offer to Acquire Abliva for $66.1 Million
GlobeNewswire
3 days ago
Pharming announces public cash offer to the shareholders of Abliva AB
MT Newswires
7 days ago
Pharming Reports Positive Phase III Data on Leniolisib in Children With Rare Primary Immunodeficiency; Shares Rise
Benzinga
7 days ago
European Biotech Pharming Group Touts Positive Data From Pivotal Pediatric Study Of FDA-Approved Immune System Disorder Drug
GlobeNewswire
7 days ago
Pharming announces positive topline data in pediatric clinical trial of leniolisib
MT Newswires
9 days ago
Jefferies Initiates Pharming Group at Buy With $14 Price Target
Simply Wall St.
15 days ago
High Growth Tech Stocks To Watch For Potential Growth
Simply Wall St.
22 days ago
Pharming Group And 2 Other Promising Penny Stocks To Watch
Compare PHAR vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "PHAR Pharming Group N.V. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.